Navigation Links
ImaginAb, Inc. and BZL Biologics, LLC Conclude Licensing Agreement for Imaging Rights to huJ591/Prostate-Specific Membrane Antigen (PSMA)
Date:10/12/2009

INGLEWOOD, Calif., Oct. 12 /PRNewswire/ -- ImaginAb, Inc. and BZL Biologics, LLC have concluded a sublicense of BZL's PSMA/huJ591 antibody technology for the field of diagnostic imaging for PET and SPECT. "ImaginAb is pleased to have completed this [sub]licensing agreement with BZL as we believe that huJ591 will form the basis of an excellent clinical product for the diagnosis and management of prostate cancer. BZL's technology has extensive human data, and we believe that huJ591 in conjunction with our antibody fragment technology will produce excellent imaging agents for PET," said Dr. Christian Behrenbruch, CEO of ImaginAb. Dr. Robert Reiter, Professor of Urology at UCLA and ImaginAb's Chief Medical Advisor further elaborated, "PSMA is an extremely significant target for prostate cancer and perhaps other solid tumors - we are excited to be validating antibody fragments against this target and plan to translate into the clinic in 2010."

"Our partnership with ImaginAb for antibody imaging with huJ591 is an important part of developing our PSMA intellectual property, and we believe that the imaging applications of our technology will result in a significant benefit to prostate cancer patient care by improving diagnostic accuracy and disease monitoring. We are also interested in working with ImaginAb to integrate imaging as part of a patient management paradigm for our PSMA-targeted therapeutics," commented Barry Silverstein, President of BZL Biologics.

About BZL Biologics

BZL Biologics, LLC is a privately held biotechnology company based in New York. Its lead program is based on antibody (Ab) targeting of PSMA, a unique cancer-related antigen that is present at high levels in all prostate cancers as well as the neo-vasculature of all types of solid tumors. This provides an exceptional platform on which to build very potent and exquisitely specific anti-tumor agents.

About ImaginAb

Founded in 2007 by UCLA Faculty (Dr. Rob Reiter and Dr. Anna Wu), ImaginAb, Inc. is an early-stage biotechnology company specializing in the development of engineered antibody fragments for diagnostic imaging and radioimmunotherapy. The company has a significant pipeline of clinical imaging agents under development oriented towards unmet needs in cancer and immunology. ImaginAb is also developing a range of pre-clinical (animal imaging) reagents for use with microPET and microSPECT systems.

SOURCE ImaginAb, Inc.


'/>"/>
SOURCE ImaginAb, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Biologics, Derma Fillers are Key to Dermatological Drug Market Growth
2. LaVoie Group Adds Bio-Surgery Company, Pegasus Biologics, to Its Life Sciences Agency Roster
3. Workforce Alliance Concludes Three-Year Biotech Training Program
4. West Concludes Agreement with Nektar
5. Exelixis and GlaxoSmithKline Agree to Successfully Conclude Six-Year Discovery and Development Collaboration
6. Cephalon Concludes All Outstanding Federal and State Government Investigations into the Companys Sales and Promotional Practices
7. BioSyntech to conclude enrolment for pivotal BST-CarGel(R) trial in February 2009
8. Ipsen and Debiopharm Conclude an Exclusive Worldwide License Agreement for the Development and Commercialisation ff the Ipsens Proprietary CDC25[1] Inhibitor (IRC-083864 or Debio 0931), an Anti-Cancer Agent
9. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
10. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
11. BioWa Announces Licensing of BioWas POTELLIGENT(R) Technology by GlaxoSmithkline for Use in Antibody Research and Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... DIEGO, CALIF. (PRWEB) , ... October 10, 2017 , ... ... as part of its corporate rebranding initiative announced today. The bold new look ... its reach, as the company moves into a significant growth period. , It will ...
(Date:10/10/2017)... ... ... Dr. Bob Harman, founder and CEO of VetStem Biopharma, Inc. spent ... entitled “Stem Cells and Their Regenerative Powers,” was held on August 31st, 2017 ... joined by two human doctors: Peter B. Hanson, M.D., Chief of Orthopedic Surgery, Grossmont ...
(Date:10/10/2017)... ... 10, 2017 , ... USDM Life Sciences , the ... sciences and healthcare industries, announces a presentation by Subbu Viswanathan and Jennifer Jaye ... GxP Validation for Agile Cloud Platforms,” will present a revolutionary approach to achieving ...
(Date:10/9/2017)... , ... October 09, 2017 , ... The award-winning American ... broadcast first quarter 2018. American Farmer airs Tuesdays at 8:30aET on RFD-TV. , ... faced with the challenge of how to continue to feed a growing nation. At ...
Breaking Biology Technology:
(Date:4/11/2017)... BROOKLYN, N.Y. , April 11, 2017 /PRNewswire-USNewswire/ ... identical fingerprints, but researchers at the New York ... University College of Engineering have found that partial ... fingerprint-based security systems used in mobile phones and ... previously thought. The vulnerability lies in ...
(Date:4/5/2017)... 5, 2017  The Allen Institute for Cell Science ... a one-of-a-kind portal and dynamic digital window into the ... the first application of deep learning to create predictive ... lines and a growing suite of powerful tools. The ... and future publicly available resources created and shared by ...
(Date:4/4/2017)... YORK , April 4, 2017   EyeLock ... today announced that the United States Patent and Trademark ... patent broadly covers the linking of an iris image ... same transaction) and represents the company,s 45 th ... latest patent is very timely given the multi-modal biometric ...
Breaking Biology News(10 mins):